Insmed Incorporated

NasdaqGS:INSM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 19.50 B

Share Price

USD 102.68

Avg Daily Volume

2,289,787

Change (1 day)

3.24%

Change (1 year)

58.68%

Change (YTD)

48.73%

Insmed Incorporated EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD -930.50 M

Insmed Incorporated EBITDA is USD -930.50 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 43.02% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Insmed Incorporated EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -650.59 M, a 33.05% change year over year.
Insmed Incorporated EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -488.98 M, a 28.88% change year over year.
Insmed Incorporated EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -379.40 M, a 38.44% change year over year.
Insmed Incorporated EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -274.05 M, a 32.69% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: INSM

Insmed Incorporated

CEO	Mr. William H. Lewis J.D., M.B.A.
IPO Date	June 1, 2000
Location	United States
Headquarters	700 US Highway 202/206
Employees	1,271
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.